Symbols / NEUP $4.59 +1.10%
NEUP Chart
About
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 24.74M |
| Enterprise Value | 2.61M | Income | -5.66M | Sales | 14.99M |
| Book/sh | 5.52 | Cash/sh | 4.11 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -1.19 | PEG | — |
| P/S | 1.65 | P/B | 0.83 | P/C | — |
| EV/EBITDA | -2.17 | EV/Sales | 0.17 | Quick Ratio | 8.76 |
| Current Ratio | 9.04 | Debt/Eq | 0.11 | LT Debt/Eq | — |
| EPS (ttm) | -0.69 | EPS next Y | -3.85 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-17 15:00 | ROA | -4.25% |
| ROE | -26.07% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -12.43% | Profit Margin | -37.79% | Shs Outstand | 5.39M |
| Shs Float | 4.17M | Short Float | 0.27% | Short Ratio | 0.53 |
| Short Interest | — | 52W High | 21.40 | 52W Low | 3.65 |
| Beta | — | Avg Volume | 49.19K | Volume | 27.65K |
| Target Price | $9.77 | Recom | None | Prev Close | $4.54 |
| Price | $4.59 | Change | 1.10% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.77
Mean price target
2. Current target
$4.59
Latest analyst target
3. DCF / Fair value
$-2.68
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.59
Low
$2.30
High
$20.00
Mean
$9.77
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-05 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-09-11 | main | Maxim Group | Buy → Buy | $35 |
| 2025-08-26 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2025-02-04 | main | HC Wainwright & Co. | Buy → Buy | $21 |
- Neuphoria Therapeutics Inc. (NEUP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Fri, 13 Mar 2026 21
- Neuphoria (NASDAQ: NEUP) receives $5.20/share non-binding interest, engages H.C. Wainwright - Stock Titan ue, 11 Nov 2025 08
- Why Did NEUP Stock Surge 64% Today? - Stocktwits Fri, 24 Oct 2025 07
- Neuphoria Therapeutics (NASDAQ:NEUP) Is In A Strong Position To Grow Its Business - simplywall.st hu, 19 Feb 2026 08
- Lynx1 Capital buys Neuphoria Therapeutics (NEUP) shares worth $3.28m - Investing.com hu, 23 Oct 2025 07
- HC Wainwright & Co. Maintains Neuphoria Therapeutics (NEUP) Buy Recommendation - Nasdaq Fri, 05 Dec 2025 08
- Why Is Neuphoria Therapeutics Stock (NEUP) Down 65% Today? - TipRanks ue, 21 Oct 2025 07
- (NEUP) Volatility Zones as Tactical Triggers - Stock Traders Daily Sat, 21 Feb 2026 09
- Neuphoria Therapeutics (NASDAQ: NEUP) sets 15% trigger; rights plan expires 2026 - Stock Titan Mon, 27 Oct 2025 07
- NEUP’s Future Prospects: Growth or Bubble? - timothysykes.com Fri, 24 Oct 2025 07
- Neuphoria stock plunges after failed anxiety disorder drug trial - Investing.com Mon, 20 Oct 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Wed, 25 Dec 2024 18
- Does This Valuation Of Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Imply Investors Are Overpaying? - simplywall.st Wed, 05 Nov 2025 08
- Ford, Intel, AMD, Neuphoria Therapeutics, Deckers Outdoor: Stocks Making The Biggest Moves Today - Stocktwits Fri, 24 Oct 2025 07
- Neuphoria Therapeutics Advances BNC-210 Trial with Prolonged Cash Runway - StocksToTrade Sun, 26 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 639110 | 3283108 | — | Purchase at price 5.14 per share. | LYNX1 CAPITAL MANAGEMENT LP | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-21 00:00:00 | I |
Financials
| Line Item | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 11.99K | -1.70K | -3.50K | 67.73K |
| TaxRateForCalcs | 0.01 | 0.01 | 0.01 | 0.02 |
| NormalizedEBITDA | -19.13M | -20.61M | -13.92M | -7.73M |
| TotalUnusualItems | 2.00M | -283.77K | -400.37K | 3.21M |
| TotalUnusualItemsExcludingGoodwill | 2.00M | -283.77K | -400.37K | 3.21M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -15.49M | -21.38M | -14.97M | -6.53M |
| ReconciledDepreciation | 662.99K | 663.19K | 763.17K | 1.28M |
| EBITDA | -17.13M | -20.90M | -14.32M | -4.51M |
| EBIT | -17.80M | -21.56M | -15.08M | -5.79M |
| NetInterestIncome | 220.10K | 323.16K | -23.59K | -1.08M |
| InterestExpense | 14.08K | 18.49K | 882.32K | |
| InterestIncome | 220.10K | 323.16K | 6.79K | 4.32K |
| NormalizedIncome | -17.48M | -21.10M | -14.57M | -9.68M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -15.49M | -21.38M | -14.97M | -6.53M |
| TotalExpenses | 17.80M | 21.56M | 14.86M | 8.96M |
| RentExpenseSupplemental | 145.85K | 180.53K | 956.01K | |
| TotalOperatingIncomeAsReported | -17.89M | -21.98M | ||
| DilutedAverageShares | 1.62M | 832.23K | 122.39M | 112.78M |
| BasicAverageShares | 1.62M | 832.23K | 122.39M | 112.78M |
| DilutedEPS | -0.23 | -18.62 | -0.16 | -0.17 |
| BasicEPS | -0.23 | -18.62 | -0.16 | -0.17 |
| DilutedNIAvailtoComStockholders | -15.49M | -21.38M | -14.97M | -6.53M |
| NetIncomeCommonStockholders | -15.49M | -21.38M | -14.97M | -6.53M |
| NetIncome | -15.49M | -21.38M | -14.97M | -6.53M |
| NetIncomeIncludingNoncontrollingInterests | -15.49M | -21.38M | -14.97M | -6.53M |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | ||
| NetIncomeContinuousOperations | -15.49M | -21.38M | -14.97M | -6.53M |
| TaxProvision | -87.32K | -139.17K | -131.95K | -140.82K |
| PretaxIncome | -15.58M | -21.52M | -15.10M | -6.68M |
| OtherIncomeExpense | 2.00M | -283.77K | -395.78K | 3.36M |
| OtherNonOperatingIncomeExpenses | 4.59K | 152.53K | ||
| SpecialIncomeCharges | -654.11K | -645.38K | 2.40M | |
| GainOnSaleOfPPE | 0.00 | -1.26K | -15.79K | |
| RestructuringAndMergernAcquisition | 654.11K | 644.13K | -2.41M | |
| GainOnSaleOfSecurity | 2.00M | -283.77K | 245.01K | 812.52K |
| NetNonOperatingInterestIncomeExpense | 220.10K | 323.16K | -23.59K | -1.08M |
| TotalOtherFinanceCost | 5.26K | 11.90K | 202.52K | |
| InterestExpenseNonOperating | 14.08K | 18.49K | 882.32K | |
| InterestIncomeNonOperating | 220.10K | 323.16K | 6.79K | 4.32K |
| OperatingIncome | -17.80M | -21.56M | -14.68M | -8.96M |
| OperatingExpense | 17.80M | 21.56M | 14.86M | 8.96M |
| OtherOperatingExpenses | -95.22K | -422.74K | -1.41M | 386.74K |
| DepreciationAmortizationDepletionIncomeStatement | 1.70M | |||
| DepreciationAndAmortizationInIncomeStatement | 1.70M | |||
| Amortization | 892.51K | |||
| AmortizationOfIntangiblesIncomeStatement | 892.51K | |||
| DepreciationIncomeStatement | 807.74K | |||
| ResearchAndDevelopment | 9.42M | 13.07M | 11.01M | 4.33M |
| SellingGeneralAndAdministration | 8.47M | 8.91M | 5.27M | 4.24M |
| GeneralAndAdministrativeExpense | 8.47M | 8.91M | 5.27M | 4.24M |
| OtherGandA | 8.47M | 8.91M | 5.09M | 3.29M |
| RentAndLandingFees | 145.85K | 180.53K | 956.01K | |
| TotalRevenue | 0.00 | 0.00 | 181.36K | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 181.36K | 0.00 |
| Line Item | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 198.71M | 1.47B | 1.35B | 1.01B |
| ShareIssued | 198.71M | 1.47B | 1.35B | 1.01B |
| TotalDebt | 272.74K | 386.92K | 477.15K | 652.04K |
| TangibleBookValue | 3.33M | 7.19M | 23.53M | 18.97M |
| InvestedCapital | 17.52M | 22.04M | 39.15M | 35.76M |
| WorkingCapital | 9.36M | 10.59M | 26.45M | 21.46M |
| NetTangibleAssets | 3.33M | 7.19M | 23.53M | 18.97M |
| CapitalLeaseObligations | 239.62K | 353.76K | 477.15K | 652.04K |
| CommonStockEquity | 17.49M | 22.01M | 39.15M | 35.76M |
| TotalCapitalization | 17.49M | 22.01M | 39.15M | 35.76M |
| TotalEquityGrossMinorityInterest | 17.49M | 22.01M | 39.15M | 35.76M |
| StockholdersEquity | 17.49M | 22.01M | 39.15M | 35.76M |
| GainsLossesNotAffectingRetainedEarnings | -3.01M | -3.06M | 8.62M | 8.60M |
| OtherEquityAdjustments | -3.01M | -3.06M | 4.75M | |
| ForeignCurrencyTranslationAdjustments | 3.85M | |||
| RetainedEarnings | -177.98M | -162.48M | -119.22M | -115.74M |
| AdditionalPaidInCapital | 198.48M | 187.55M | ||
| CapitalStock | 11.00 | 0.00 | 149.75M | 142.90M |
| CommonStock | 11.00 | 0.00 | 149.75M | 142.90M |
| TotalLiabilitiesNetMinorityInterest | 10.16M | 6.55M | 5.78M | 5.01M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 6.33M | 3.81M | 3.47M | 3.23M |
| OtherNonCurrentLiabilities | 590.65K | 2.47M | 1.86M | 1.32M |
| DerivativeProductLiabilities | 4.66M | 0.00 | ||
| EmployeeBenefits | 22.40K | 7.20K | 5.10K | |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 6.78K | |||
| NonCurrentDeferredLiabilities | 963.54K | 1.10M | 1.24M | 1.38M |
| NonCurrentDeferredTaxesLiabilities | 963.54K | 1.10M | 1.24M | 1.38M |
| LongTermDebtAndCapitalLeaseObligation | 117.63K | 239.84K | 367.06K | 521.14K |
| LongTermCapitalLeaseObligation | 117.63K | 239.84K | 367.06K | 521.14K |
| CurrentLiabilities | 3.83M | 2.74M | 2.31M | 1.77M |
| OtherCurrentLiabilities | 37.58K | 39.41K | ||
| CurrentDebtAndCapitalLeaseObligation | 155.11K | 147.08K | 110.09K | 130.90K |
| CurrentCapitalLeaseObligation | 121.99K | 113.93K | 110.09K | 130.90K |
| CurrentDebt | 33.12K | 33.15K | ||
| OtherCurrentBorrowings | 33.12K | 33.15K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 457.02K | 281.58K | 279.45K | |
| PayablesAndAccruedExpenses | 3.64M | 2.55M | 1.92M | 1.36M |
| CurrentAccruedExpenses | 1.39M | 1.11M | 845.72K | 590.29K |
| Payables | 2.24M | 1.44M | 1.07M | 772.93K |
| OtherPayable | 590.29K | |||
| AccountsPayable | 2.24M | 1.44M | 1.07M | 772.93K |
| TotalAssets | 27.65M | 28.56M | 44.93M | 40.77M |
| TotalNonCurrentAssets | 14.46M | 15.24M | 16.17M | 17.53M |
| OtherNonCurrentAssets | 78.83K | 78.90K | 81.86K | 89.41K |
| NonCurrentPrepaidAssets | 89.41K | |||
| InvestmentsAndAdvances | 119.00K | |||
| OtherInvestments | 119.00K | |||
| GoodwillAndOtherIntangibleAssets | 14.16M | 14.82M | 15.62M | 16.79M |
| OtherIntangibleAssets | 5.47M | 6.13M | 6.77M | 7.47M |
| Goodwill | 8.69M | 8.69M | 8.85M | 9.32M |
| NetPPE | 218.97K | 333.00K | 464.02K | 654.37K |
| AccumulatedDepreciation | -45.72K | -45.24K | -173.36K | -1.21M |
| GrossPPE | 218.97K | 378.24K | 637.37K | 1.86M |
| Leases | 854.50K | 587.82K | 1.78M | |
| OtherProperties | 218.97K | 330.48K | 1.78M | |
| MachineryFurnitureEquipment | 47.72K | 47.76K | 49.55K | 80.21K |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 13.19M | 13.33M | 28.76M | 23.24M |
| OtherCurrentAssets | 699.43K | |||
| RestrictedCash | 0.00 | 327.31K | ||
| PrepaidAssets | 458.76K | 797.48K | 1.01M | 646.75K |
| Receivables | 126.88K | 426.09K | 4.67M | 849.85K |
| OtherReceivables | 96.15K | 416.07K | 4.65M | 844.35K |
| TaxesReceivable | 30.44K | 9.76K | 15.05K | 5.51K |
| AccruedInterestReceivable | 286.00 | 257.00 | ||
| AccountsReceivable | 144.77K | |||
| GrossAccountsReceivable | 144.77K | |||
| CashCashEquivalentsAndShortTermInvestments | 12.61M | 12.10M | 23.09M | 21.41M |
| OtherShortTermInvestments | 327.31K | |||
| CashAndCashEquivalents | 12.61M | 12.10M | 23.09M | 21.41M |
| CashFinancial | 18.25M | 23.09M | 21.41M |
| Line Item | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -14.68M | -14.64M | -14.97M | -5.67M |
| RepurchaseOfCapitalStock | -415.48K | |||
| RepaymentOfDebt | -105.94K | -119.85K | -8.92M | |
| IssuanceOfCapitalStock | 10.11M | 3.86M | 22.63M | 32.94M |
| CapitalExpenditure | -1.06K | -1.10K | ||
| InterestPaidSupplementalData | 726.42K | |||
| EndCashPosition | 12.69M | 12.18M | 23.09M | 21.41M |
| BeginningCashPosition | 12.18M | 23.21M | 19.61M | 3.44M |
| EffectOfExchangeRateChanges | 76.97K | -243.82K | -547.87K | -9.82K |
| ChangesInCash | 428.02K | -10.78M | 4.03M | 17.98M |
| FinancingCashFlow | 15.11M | 3.86M | 18.57M | 23.71M |
| CashFlowFromContinuingFinancingActivities | 15.11M | 3.86M | 18.57M | 23.71M |
| NetOtherFinancingCharges | -1.13M | -3.94M | -312.16K | |
| ProceedsFromStockOptionExercised | 5.00M | 0.00 | ||
| NetCommonStockIssuance | 10.11M | 3.86M | 22.63M | 32.94M |
| CommonStockPayments | -415.48K | |||
| CommonStockIssuance | 10.11M | 3.86M | 22.63M | 32.94M |
| NetIssuancePaymentsOfDebt | -105.94K | -119.85K | -8.92M | |
| NetLongTermDebtIssuance | -105.94K | -119.85K | -8.92M | |
| LongTermDebtPayments | -105.94K | -119.85K | -8.92M | |
| InvestingCashFlow | 317.41K | 427.68K | -60.26K | |
| CashFlowFromContinuingInvestingActivities | 317.41K | 427.68K | -60.26K | |
| InterestReceivedCFI | 317.41K | 8.61K | 3.08K | |
| NetInvestmentPurchaseAndSale | 0.00 | 299.68K | -89.01K | |
| SaleOfInvestment | 0.00 | 299.68K | 0.00 | |
| PurchaseOfInvestment | 0.00 | 0.00 | -89.01K | |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | ||
| PurchaseOfBusiness | 0.00 | 0.00 | ||
| NetPPEPurchaseAndSale | 0.00 | 119.38K | 25.67K | |
| SaleOfPPE | 0.00 | 120.45K | 26.77K | |
| PurchaseOfPPE | 0.00 | -1.06K | -1.10K | |
| OperatingCashFlow | -14.68M | -14.64M | -14.97M | -5.66M |
| CashFlowFromContinuingOperatingActivities | -14.68M | -14.64M | -14.97M | -5.66M |
| ChangeInWorkingCapital | 1.45M | 4.58M | -3.85M | 1.23M |
| ChangeInOtherWorkingCapital | -139.17K | -139.17K | -103.70K | -182.84K |
| ChangeInOtherCurrentLiabilities | -126.11K | -99.77K | 0.00 | 0.00 |
| ChangeInOtherCurrentAssets | 170.95K | -412.94K | -64.35K | |
| ChangeInPayablesAndAccruedExpense | 1.08M | 512.25K | 674.08K | -47.56K |
| ChangeInAccruedExpense | 277.85K | 138.08K | ||
| ChangeInPayable | 804.37K | 374.18K | 674.08K | -47.56K |
| ChangeInAccountPayable | 804.37K | 374.18K | ||
| ChangeInPrepaidAssets | 338.71K | 173.97K | ||
| ChangeInInventory | 0.00 | 0.00 | ||
| ChangeInReceivables | 299.20K | 4.14M | -4.01M | 1.52M |
| ChangesInAccountReceivables | 299.20K | 4.14M | -26.93K | 25.60K |
| OtherNonCashItems | -1.75M | 707.75K | 637.34K | -1.83M |
| StockBasedCompensation | 814.81K | 1.35M | 1.95M | 983.01K |
| DepreciationAmortizationDepletion | 662.99K | 663.19K | 763.17K | 1.28M |
| DepreciationAndAmortization | 662.99K | 663.19K | 763.17K | 1.28M |
| OperatingGainsLosses | -366.33K | -556.78K | 509.22K | -786.45K |
| GainLossOnInvestmentSecurities | -338.98K | |||
| NetForeignCurrencyExchangeGainLoss | -27.35K | -556.78K | 507.97K | -802.24K |
| GainLossOnSaleOfPPE | 0.00 | 0.00 | ||
| NetIncomeFromContinuingOperations | -15.49M | -21.38M | -14.97M | -6.53M |
| CashFlowsfromusedinOperatingActivitiesDirect | -5.66M | |||
| InterestPaidDirect | -545.79K | |||
| ClassesofCashPayments | -7.61M | |||
| PaymentstoSuppliersforGoodsandServices | -7.61M | |||
| ClassesofCashReceiptsfromOperatingActivities | 2.49M | |||
| ReceiptsfromGovernmentGrants | 2.19M | |||
| ReceiptsfromCustomers | 296.64K |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NEUP
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|